Merck's Enflonsia vaccine for respiratory syncytial virus won approval from the Centers for Disease Control and Prevention's ...

Merck & Co., Inc. (NYSE:MRK) is one of the 10 Best Value Stocks to Buy According to Billionaires. The company announced that ...

The FDA delivered two notable approvals for RSV immunization, UroGen overcame a negative advisory committee vote to secure an ...

A newly configured federal vaccine panel's June 25 action is expected to improve options to protect infants from potentially ...

An outside group of experts agreed that the CDC should recommend a new antibody drug that offers protection against RSV for ...

Robert F. Kennedy Jr.’s vaccine advisory committee recommended Merck & Co.’s shot to prevent newborns from getting RSV, ...

CDC panel backs Merck's Enflonsia for RSV prevention in infants; FDA-approved therapy reduced hospitalizations by 84% in ...

US pharma major Merck & Co has secured a key endorsement for its newly approved respiratory syncytial virus (RSV) prevention ...

Rahway: Merck, known as MSD outside of the United States and Canada, has announced the U.S. Centers for Disease Control and ...

Enjoy, and see you soon… A fast-growing group of Americans is turning to what many call the “gray market” for obesity ...

The votes on vaccine recommendations are the first move by the panel after Health and Human Services Secretary Robert F.

The ACIP is recommending the use of Enflonsia for the prevention of RSV lower respiratory tract disease in infants younger than 8 months.